Home Corporate Overview | Products | Services | Research & Development | Media Room | Careers
    | |
 
  Shanvac-B
  Shanferon
 
  Shantetra
Cytocrest
  Shan5
  Shan Hib-DPT
  Shan Hib
  ShanTT
 
Quick Tour
   
 
Corporate
Film
 
Corporate
Presentation
   
Corporate
Gallery
   
Disease Awareness
   
 
 
   
 
 
 
 
 
In an effort to enrich and prolong the life of cancer patients through cost-effective therapies, Shantha has launched the CYTOCREST initiative.

Under this initiative, Shantha will introduce several new generation Oncocare products which will be either developed in-house or through alliances with major pharmaceutical companies.

The whole gamut of therapies in cancer care has been planned under the flagship of CYTOCREST which includes Chemotherapeutics, Biological Therapy and Supportive Therapy, for marketing in India only.
 
     
 
Epricin Shancyte Zoledron Platoxin Shanferon
Captabin Shanmyde M-Fost Paxytol Cistriz
Talimyde Doxel Shantroz